United States

Modern US psychedelic policy still rests on the Controlled Substances Act framework and DEA scheduling. Under that federal baseline, psilocybin, psilocin, LSD, MDMA, DMT, 5-MeO-DMT, ibogaine and mescaline remain Schedule I, which means no recognised medical use under federal law and correspondingly tighter research controls. Ketamine followed a different path: DEA placed it in Schedule III in 1999, preserving ordinary medical use while keeping it under controlled-substances rules.###

That split matters historically. Ketamine entered routine medicine decades ago as an anaesthetic and later became the foundation for a much broader psychiatric practice ecosystem through off-label prescribing, while esketamine moved through the formal FDA process and gained psychiatric approval in 2019, later adding further label expansion. The clinic economy that followed racemic ketamine is therefore not evidence of psychedelic legalisation; it is an outgrowth of ordinary off-label practice around a Schedule III drug that already had FDA approval for a different indication.####

The research restart in classic psychedelics has been driven largely by academic centres and federally authorised IND work rather than by state legalisation. Johns Hopkins launched its dedicated centre in 2019, NYU Langone established its own centre in 2021, and NIDA and NIMH now publish formal research-facing material on psychedelics and related compounds. FDA's 2023 guidance made that shift more explicit by giving sponsors a formal framework for clinical-development design.####

MAPS/Lykos's MDMA development effort became the most visible attempt to convert that research revival into a first-in-class federal authorisation for a classic psychedelic-related therapy. FDA's June 2024 advisory-committee review and August 2024 complete response letter showed that the agency was not prepared to accept the package as submitted. In practical terms, that setback reset expectations not just for MDMA but for the evidentiary bar across psychedelic drug development.#

State reform then accelerated on a separate track. Oregon voters created the first psilocybin services framework, Colorado followed with a natural medicine system, DC adopted a lowest-priority policing model for entheogenic plants and fungi, and later states turned to hybrid models ranging from New Mexico's supervised medical programme to Texas's ibogaine development law and Utah's research-first legislation. The national picture is therefore a convergence of three histories: federal prohibition, academic/clinical revival, and state experimentation.#####

Oregon and Portland#

Oregon is the clearest proof that a state can run a licensed psychedelics service market without claiming to create medical treatment. OHA's model is adult, supervised and non-prescription based. Portland matters because it concentrates service centres, facilitators, training activity and media attention around the first functioning US system of this type.##

Colorado and Denver#

Colorado matters because it is building the next major state system and because its regulators have had to design a more complex natural medicine architecture than Oregon's. Denver remains the symbolic and practical centre of that process because the state's licensing, training, compliance and stakeholder conversations are concentrated there. As of February 2026, public state data showed approved healing-centre applications, but the number of actually operating centres still needs direct manual verification.##

California, the Bay Area and Los Angeles#

California remains the country's largest research and ecosystem state rather than a service-access state. The Research Advisory Panel of California continues to review Schedule I/II studies; UCSF and Stanford are active in psilocybin pain and neuroimaging work; and UCLA appeared in RAPC meeting materials as part of the ongoing research pipeline. Los Angeles and the Bay Area also matter because they combine academic medicine, biotech formation and philanthropy.##

Maryland and Washington DC#

This corridor matters for two different reasons. Baltimore is home to Johns Hopkins, which remains one of the field's most influential academic centres. Washington DC matters not because it created a clinical market, but because it is where federal policy, litigation, agency signalling and lowest-priority local reform intersect in the same geography.##

New York#

New York's importance rests on institutional density rather than permissive state law. NYU Langone's Center for Psychedelic Medicine is one of the flagship East Coast centres and remains active across cancer-related distress, addiction, depression and neurobiological mechanism work. New York also remains a media, philanthropy and professional-network hub for the field.#

Texas and the Austin-Houston-Galveston corridor#

Texas now matters nationally because it is the most ambitious public-sector ibogaine state. The state's policy is not liberal access; it is industrial-scale drug-development ambition tied to veterans, addiction and brain-injury narratives. Austin matters politically, while Houston and Galveston matter because UTHealth Houston and UTMB have been identified in reporting around the research effort.##

New Mexico, Arizona and Utah###

Taken together, these states form a notable south-western policy laboratory. New Mexico is building a supervised medical psilocybin programme; Arizona chose bounded grant-funded psilocybin research; Utah has kept the narrowest and most conservative evidence-first approach, first through healthcare-system pilot authority and then through a veteran PTSD study. None of the three should be described as broad psychedelic legalisation.###

Over the next 12 to 24 months, the likeliest changes are not nationwide psychedelic legalisation but incremental movement across separate channels. Evidence development should continue in psilocybin, LSD/MM120, ketamine/esketamine and ibogaine-related programmes, with academic centres and sponsor-led multicentre work continuing to define the field. FDA's April 2026 announcement suggests a more active federal posture on study design and development support, but not a lowered approval bar. The midomafetamine/PTSD experience indicates that classic psychedelic approval will still depend on unusually robust trial design, clean safety narratives and high confidence in psychotherapy standardisation and data integrity.####

COMP360 should be treated as the main near-term FDA watch item for psilocybin. The practical question is not whether psilocybin is broadly legal, but whether a sponsor-led synthetic psilocybin medicine can move through rolling NDA review and then into scheduling, REMS-like controls, coverage decisions and provider training. Approval remains uncertain until FDA completes review.###

At state level, Oregon is likely to deepen operationally rather than change category; Colorado is likely to move from implementation architecture to more visible real-world service delivery; and New Mexico is likely to stay focused on rulemaking, training and infrastructure rather than broad immediate enrolment. Texas and Utah are likely to be watched as test cases for publicly backed research-first models, with Texas focused on ibogaine drug development and Utah on tightly supervised veteran PTSD research.#####

Reimbursement is the least likely area to liberalise quickly outside esketamine and existing ketamine channels. Medicare, VA and some commercial plans already provide viable esketamine payment routes, but state psilocybin and natural medicine systems are likely to remain predominantly self-pay while substances stay federally illegal and outside standard drug-benefit structures. Off-label ketamine will remain available, but regulator and payer scrutiny of compounded at-home and telemedicine-heavy models is likely to continue.#####

The biggest uncertainty is timing. Colorado's real operating footprint, New Mexico's first-patient timeline, Texas's consortium mechanics, and any resubmission strategy after the Lykos complete response letter are all moving targets. For publication, those should be treated as implementation questions rather than settled facts.####